Prestige Consumer Healthcare has spent two decades doing something quietly difficult: buying unglamorous drugstore brands, Clear Eyes, Chloraseptic, Monistat, and running them for cash. No blockbuster pipeline, no patent cliff drama. Just steady margins on products people reach for when they feel lousy. That model earned the stock a comfortable valuation for most of its history. Then, over the past year, the stock fell sharply, and the market stopped paying for it at all.
The tension sitting at the center of this story is simple to state and hard to dismiss. The filed numbers show a business that has held its net margin near 19% for two of the last four fiscal years, with FY2022 also coming in near that level before the period. The price today implies the market thinks that record is worth almost nothing. Both readings cannot be right at the same time, and that disagreement is what this piece is about.
What matters here
The filings show Prestige has earned roughly nineteen cents of profit on every dollar of sales in most recent years, a level of profitability that has barely moved despite flat revenue. The stock is now priced at a multiple, meaning the price tag per dollar of profit, that sits at the fifth percentile of its own decade, our data show. The open question is whether a real deterioration in the business justifies that discount, or whether the market is pricing in a collapse that the filed numbers do not yet support.
What the filings actually show
Start with the most recent full fiscal year. The 10-K for the year ended March 31, 2026 shows revenue just below $1.1 billion and a net margin of 17.5%, down modestly from the prior year. That dip is real and worth watching. But look at the four-year run: FY2025, FY2024, and FY2022 all came in within a whisker of 19%. The business has been a margin-consistency machine, with one jarring exception in FY2023, when a goodwill write-down pushed net income negative. Strip that accounting event out and the underlying profitability story barely flinches across five years.
The most recent quarterly filing adds a wrinkle. The 10-Q for the quarter ended June 30, 2026 shows the fastest top-line growth in several years, yet GAAP net income fell roughly two-fifths from the same quarter a year earlier. Adjusted gross margin slipped by more than a full percentage point. Revenue is growing; profit per dollar of that revenue is shrinking. That is the specific tension inside the most recent quarter, and it is what the market appears to be pricing.
The acquisition bet hiding in the numbers
The revenue growth in Q1 FY2027 did not come from organic momentum. It came from deals. Prestige acquired the Breathe Right portfolio in June 2026 and LaCorium Health in July 2026, according to the Barclays conference transcript. Management said at that conference that pro forma sales, meaning what revenue looks like with those acquisitions included from the start, are approaching $1.4 billion, a business meaningfully larger than what the filings show today.
Acquisitions of this kind are a familiar move for Prestige. The company bought Pillar5 Pharma in December 2023 specifically to secure its own manufacturing for Clear Eyes, its biggest brand, after supply disruptions hurt revenue. The Breathe Right deal, at roughly $1 billion according to the PitchBook record, is the largest single bet in recent memory. Debt comes with it. The enterprise value, the market cap plus net debt, sits near $4.5 billion against a market cap of roughly half that, meaning the company owes roughly as much as the entire equity is worth. That leverage is not disqualifying for a cash-generative business, but it does mean the margin story matters more, not less, because every point of margin lost is a point that would otherwise pay down debt.
What the price is assuming
Here is where the math and the mood diverge most sharply. The math, meaning what the filed fundamentals describe, is a business earning near-19% net margins with a new revenue base approaching $1.4 billion. The mood, meaning what the market is currently paying, is a price-to-earnings multiple of 13.2 times, against a decade median of 14.8 times, our data show.
To feel what that means: if a business normally sells for roughly fifteen times its annual earnings and today sells for thirteen times, the market is saying either that earnings are about to fall sharply, or that the business deserves a permanently lower rating than its own history suggests. The filed numbers do not yet show a structural collapse. The margin dipped in the most recent fiscal year and compressed further in the latest quarter, but the compression is measured in single percentage points, not the kind of break that would justify a discount this deep on its own.
The Clear Eyes supply disruption is the most concrete explanation on offer. That franchise is the company’s largest, and when supply ran short, revenue fell and costs did not fall with it, which is exactly how margins compress. Management said at the Q4 FY2026 earnings call that recovery depends on supply returning in the second half of FY2027. If that recovery arrives, the margin picture looks different. If it does not, the current discount has more to say for itself.
Reading the numbers
Net margin, FY2022 to FY2026 (filed). What it is: the share of each revenue dollar left after every cost, including taxes. What it means here: Prestige has held this figure between 17.5% and 18.9% in four of the last five years, per the FY2026 10-K and prior filings. Everyday translation: a shop that rings up $100 in sales keeps about $18.50 after paying for everything. That is a high-quality result for a consumer products company, and its consistency is the core of the bull case.
P/E at 13.2 times, decade median 14.8 times (our data). What it is: the multiple, or price tag per dollar of annual profit. What it means here: the stock is priced at roughly 89% of its historical norm. Everyday translation: a business that normally sells for $14.80 per dollar of profit is on offer today for $13.20. The gap is either a discount the market will eventually close, if margins recover toward their historical range, or a rational re-rating, if the compression proves structural. The filed numbers do not yet resolve which reading is correct.
Q1 FY2027 GAAP net income down 39% year over year, per the 10-Q filed for the quarter ended June 30, 2026. What it is: the single-quarter profit drop despite revenue growing 6.5%. What it means here: the acquisitions added sales but also added costs, interest, and integration drag faster than they added profit. Everyday translation: a household that takes on a second job sees its gross income rise but its take-home fall because the commuting costs and taxes on the extra income eat the gain. The question is whether that is temporary or structural.
Enterprise value near $4.5 billion against a $2.2 billion market cap (our data, as of September 11, 2026). What it is: the total price to own the whole business, debt included. What it means here: a buyer of the equity is also implicitly assuming roughly $2.3 billion in net obligations. For a business generating around $250 million in annual free cash flow, per management’s guidance at the Q4 call, that debt load takes roughly nine years to retire at current rates, leaving less room for error than the pre-acquisition balance sheet did.
The data cannot answer whether the Clear Eyes recovery arrives on management’s timeline, or whether the acquisition costs compress margins for longer than one or two quarters. Those are the open questions. What the filings do answer is that the underlying margin engine, before the disruption and before the deals, was real and durable. Whether today’s price reflects a temporary storm or a permanent reset is the central analytical question the filed evidence leaves open, one the market has not yet resolved.
Sources
- SEC EDGAR: PBH 10-Q, quarter ended June 30, 2026
- SEC EDGAR: PBH 10-K, fiscal year ended March 31, 2026
- SEC EDGAR: PBH 10-K, fiscal year ended March 31, 2025
- SEC EDGAR: PBH 10-K, fiscal year ended March 31, 2024
- PBH Q4 FY2026 earnings call summary, StockTaper
- Prestige Consumer Healthcare at Barclays Conference transcript, Investing.com
- PBH P/E ratio data, Public.com, as of September 11, 2026
- PBH company profile, PitchBook
- PBH overview, SimplyWall St
